Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Duragesic® (fentanyl) Therapeutic Transdermal System (TTS), Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)
Duragesic Therapeutic System · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| Duragesic® (fentanyl) Therapeutic Transdermal System (TTS) | DRUG | - |
| Duragesic® (fentanyl) Transdermal Therapeutic System (TTS) | DRUG | - |
Inclusion Criteria: * Patients suffering from chronic pain of a well documented cause that requires continuous administration of opioids * Received opioids continuously for a minimum of 7 days prior to enrollment with a projected need for continuous opioids for at least the length of the primary tr...
Top 4 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Retatrutide, LY3016859, LY3556050, LY3526318, LY3857210 |
| Fortress Biotech, Inc. | FBIO | 1 | PHASE3 | Tramadol |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | MK-6916 |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
Duragesic Therapeutic System is a fentanyl transdermal patch developed by Johnson & Johnson for chronic pain. It delivers the small molecule fentanyl through the skin for continuous narcotic pain relief therapy. It is studied in patients with chronic pain, including pediatric patients aged 2 years and older who require narcotic pain relief.
Duragesic Therapeutic System is used for the treatment of chronic pain in patients requiring narcotic pain relief therapy. Its clinical program includes children with chronic pain and children with continuous pain who need ongoing opioid analgesia. The patch is designed to provide continuous delivery rather than intermittent dosing.
Duragesic Therapeutic System is developed by Johnson & Johnson, which trades under the ticker JNJ. Johnson & Johnson is the sponsor of the clinical trials evaluating the fentanyl transdermal patch in chronic pain, including the pediatric studies registered as NCT00271466 and NCT00271414.
Duragesic Therapeutic System has been evaluated in Phase 3 clinical trials. Two Phase 3 studies are registered, both listed as completed, with no trials currently active. The program enrolled a total of 252 participants across the two completed studies in chronic pain.
Two completed Phase 3 trials are registered for Duragesic Therapeutic System. NCT00271466 assessed safety, dose conversion, and dose individualization in children with chronic pain requiring narcotic therapy and enrolled 199 participants. NCT00271414 was a 15-day study of safety and clinical utility in children with continuous pain and enrolled 53 participants.
Yes. Duragesic Therapeutic System is also known as Duragesic (fentanyl) Therapeutic Transdermal System (TTS), Duragesic (fentanyl) Transdermal Therapeutic System (TTS), and Duragesic Therapeutic System. These names refer to the same fentanyl transdermal patch developed by Johnson & Johnson for chronic pain.